Free Deal Calculator

Calculate CAR-T Solid Tumor Deal Values Instantly

Get accurate licensing valuations with premium market data for high-potential solid tumor CAR-T therapies

Premium Market Intelligence

Access specialized CAR-T solid tumor data with 40% premium valuations. Our calculator reflects the high-risk, high-reward nature of this cutting-edge modality.

Instant Deal Structuring

Generate comprehensive term sheets in minutes, not weeks. Calculate upfront payments, milestones, and royalties based on real Phase 2+ deal benchmarks.

Validated by Leaders

Built with input from top biotech BD executives and investors. Our models accurately predict deal values from $700M to $2.5B total consideration.

$2.5B

Max Deal Values Calculated

40%

Solid Tumor Premium Applied

$60M+

Typical Phase 2 Upfronts

500+

CAR-T Deals Benchmarked

How It Works

Input Your Asset Profile

Enter CAR-T solid tumor details: target, development stage, preclinical data, and competitive landscape position.

Apply Market Premiums

Our algorithm applies the 40% solid tumor premium and adjusts for risk factors specific to CAR-T cell therapy.

Generate Deal Terms

Receive detailed valuation report with upfront ($60M-$250M range), milestones, royalties, and comparable deal analysis.

Frequently Asked Questions

Why do CAR-T solid tumor deals command premium valuations?

Solid tumor CAR-T represents the next frontier with massive market potential. Despite technical challenges, successful programs can address $100B+ oncology markets, justifying 40% premiums over hematologic CAR-T deals.

What Phase 2 upfront should I expect for my CAR-T program?

CAR-T solid tumor Phase 2 upfronts typically range $60M-$250M, depending on target validation, safety profile, and preliminary efficacy data. Our calculator factors in these variables for accurate estimates.

How accurate are the total deal value projections?

Our models analyze 500+ CAR-T transactions to predict total deal values of $700M-$2.5B. Accuracy improves with more clinical data - Phase 2+ programs show 85% correlation with actual deal terms.

Can this handle novel CAR-T approaches like dual-targeting?

Yes, our calculator includes premium adjustments for innovative approaches including dual CAR, armored CAR-T, and next-gen engineering. Novel mechanisms typically add 15-25% to base valuations.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating